Literature DB >> 26870205

Recombinant adenovirus expressing hIFN-λ1 inhibits gastric adenocarcinoma cell line SGC-7901 proliferation.

Xuefeng Bu1, Mubin Wang2, Jie Zhang2, Jun Liu2, Lijuan Jia3, Bing Liang3, Yulan Yan4.   

Abstract

The aim of the present study is to investigate the effect of a recombinant plasmid adenovirus (pAd) expressing human interferon-λ1 (hIFN-λ1) on the proliferation of the gastric adenocarcinoma cell line SGC-7901. For this purpose, human gastric adenocarcinoma SGC-7901 cells were infected with recombinant pAd-hIFN-λ1, pAd-LacZ and phosphate-buffered saline (PBS), respectively, and the subsequent effects on the proliferation of the infected cells were compared. Cell proliferation was evaluated by MTT assay, while mRNA and protein expression of hIFN-λ1 were detected by reverse transcription-polymerase chain reaction analysis and immunofluorescence assay, respectively. In addition, terminal deoxynucleotidyl transferase deoxyuridine triphosphate nick end labeling assay and flow cytometry were conducted to analyze the rate of cell apoptosis. The results indicated that the proliferation of gastric adenocarcinoma SGC-7901 cells was significantly inhibited by pAd-hIFN-λ1. Furthermore, the apoptosis rate and the mRNA and protein expression levels of hIFN-λ1 were higher in pAd-hIFN-λ1-transfected cells, compared with the pAd-LacZ and PBS control groups. In conclusion, recombinant pAd-hIFN-λ1 induced the expression of hIFN-λ1 in gastric adenocarcinoma SGC-7901 cells, and significantly inhibited cell proliferation by promoting apoptosis in these cancer cells.

Entities:  

Keywords:  apoptosis; gastric cancer; interferon-λ; recombinant adenovirus

Year:  2015        PMID: 26870205      PMCID: PMC4727041          DOI: 10.3892/ol.2015.3890

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Antitumor activities of recombinant human interferon (IFN)-λ1 in vitro and in xenograft models in vivo for colon cancer.

Authors:  Xiwu Hui; Hong Chen; Shenghua Zhang; Xiaoli Ma; Xin Wang; Bingren Huang
Journal:  Cancer Lett       Date:  2011-07-14       Impact factor: 8.679

2.  Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma.

Authors:  Ahmed Lasfar; Anita Lewis-Antes; Sergey V Smirnov; Shubha Anantha; Walid Abushahba; Bin Tian; Kenneth Reuhl; Harold Dickensheets; Faruk Sheikh; Raymond P Donnelly; Elizabeth Raveche; Sergei V Kotenko
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

Review 3.  Interferons lambda, new cytokines with antiviral activity.

Authors:  K Lopušná; I Režuchová; T Betáková; L Skovranová; J Tomašková; L Lukáčiková; P Kabát
Journal:  Acta Virol       Date:  2013       Impact factor: 1.162

4.  Enhanced exposure of phosphatidylserine in human gastric carcinoma cells overexpressing the half-size ABC transporter BCRP (ABCG2).

Authors:  Holger Woehlecke; Antje Pohl; Nele Alder-Baerens; Hermann Lage; Andreas Herrmann
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

Review 5.  Adenoviral gene therapy in gastric cancer: a review.

Authors:  Nima Khalighinejad; Hesammodin Hariri; Omid Behnamfar; Arash Yousefi; Amir Momeni
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

6.  Inhibition of lung adenocarcinoma transfected with interleukin 28A recombinant adenovirus (Ad-mIFN-λ2) in vivo.

Authors:  Yulan Yan; Jin Zhang; Yang Liu; Taofeng Zhu; Lixue Yuan; Yuxi Ge; Hao Ding; Xuefeng Bu
Journal:  Cancer Biother Radiopharm       Date:  2012-11-07       Impact factor: 3.099

Review 7.  Novel type III interferons produce anti-tumor effects through multiple functions.

Authors:  Quanhai Li; Kiyoko Kawamura; Yuji Tada; Hideaki Shimada; Kenzo Hiroshima; Masatoshi Tagawa
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

Review 8.  Interferon lambdas: the next cytokine storm.

Authors:  Christabel Kelly; Paul Klenerman; Eleanor Barnes
Journal:  Gut       Date:  2011-02-08       Impact factor: 23.059

Review 9.  Burden of gastrointestinal cancer in Asia; an overview.

Authors:  Mohamad Amin Pourhoseingholi; Mohsen Vahedi; Ahmad Reza Baghestani
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2015

Review 10.  Update on taxane development: new analogs and new formulations.

Authors:  Jean A Yared; Katherine H R Tkaczuk
Journal:  Drug Des Devel Ther       Date:  2012-12-11       Impact factor: 4.162

View more
  1 in total

Review 1.  The role of IL-29 in immunity and cancer.

Authors:  Noah E Kelm; Ziwen Zhu; Vivi A Ding; Huaping Xiao; Mark R Wakefield; Qian Bai; Yujiang Fang
Journal:  Crit Rev Oncol Hematol       Date:  2016-08-10       Impact factor: 6.312

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.